How do you counsel patients on the potential benefits of nerandomilast for PPF?

I reference the FIBRONEER-ILD trial with nerandomilast, which improved outcomes (including mortality) in the setting of fibrotic lung disease with progression (including CTD-associated fibrotic ILD), provided the patient met the diagnostic criteria (including a diagnosis of fibrotic lung disease wit...

I would frame the benefit as preservation rather than improvement. The goal is to slow the additional loss of lung function over time.

In FIBRONEER-ILD, patients receiving placebo lost about 166 mL FVC over a year, compared with 99 mL on nerandomilast 18 mg and 85 mL with 9 mg. This translated into a...

Nerandomilast is an inhibitor of phosphodiesterase 4 (PDE4), which leads to elevated intracellular cAMP, which reduces the expression of profibrotic cytokines and growth factors. It has both antifibrotic and immunomodulatory activity and may be useful in active inflammatory ILD based on these charac...